Intravenous self-administration of MK-801 by rhesus monkeys with cocaine and phencyclidine self-administration histories. P.M. Beardsley, J.M. Salay and R.L. Baister, Medical College of Virginia.

Influence of physical dependence on the reinforcing effects of drugs. Y. Wakasa, K. Takada and T. Yanagita, Central Institute for Experimental Animals, Japan.

Oral self-administration of pentobarbital by rhesus monkeys under concurrent fixed-ratio schedules: Relative reinforcing effects of different pentobarbital concentrations and volumes. R.A. Meisch and G.A. Lemaitre, University of Minnesota Medical School.


Limited access to nicotine self-administration in rodents. W.A. Corrigall and K.M. Coen, Addiction Research Foundation and University of Toronto, Canada.

The role of smoke inhalation versus changes in draw in accounting for the decreases in puff volume which occur as a cigarette is smoked. P.P. Woodson and R.R. Griffiths, The Johns Hopkins University School of Medicine.

Effects of drug history and response cost on the self-administration of nicotine in humans. J.R. Hughes, University of Vermont.

Effects of food deprivation on subjective responses to d-amphetamine in humans. J.P. Zacny and H. de Wit, University of Chicago.

ISGIDAR BUSINESS MEETING

Treasurer David Downs reported that the current balance of the ISGIDAR account is $1777.44, which includes $510 collected at this year's meeting.

President Nancy Ator reported that for the second year there were no submissions for the Student Paper Competition Award. ISGIDAR members are strongly encouraged to publicize the availability of these travel funds to doctoral students and recent graduates. (Details on eligibility and application procedures are described in this Newsletter.)

President Ator updated members on the current status of the new federal animal care regulations. ISGIDAR members will be notified as soon as a new draft of the regulations is available, so that they can submit their comments on the proposed revisions. (Editor's note: Since the ISGIDAR meeting, we have obtained information that the new regulations have been drafted but will probably not be available for comment until after November.) Bill Woolverton reported that he, Patrick Beardsley, Marilyn Carroll and Nancy Ator have prepared a manuscript discussing the issue of "psychological well-being" of laboratory animals, in anticipation of the proposed regulation on this topic. This manuscript is available to ISGIDAR members from Bill Woolverton. (Dept. of Pharmacological and Physiological Sciences, University of Chicago, 947 E. 58th St., Chicago, IL 60637).

It was announced that ISGIDAR would meet in 1989 at Keystone, Colorado, the week of June 19th. As usual, ISGIDAR will meet as a satellite session of the Committee on Problems of Drug Dependence. There was some discussion as to the future of joint meetings with the Society for Stimulus Properties of Drugs. There was a consensus that the identity of ISGIDAR should be preserved, and that our traditional meeting day (the day preceding CPDD) should be continued. As a mechanism for broadening the base of ISGIDAR participation, Marilyn Carroll moved and John Roache seconded that we offer five $100 honorariums to speakers who would be invited to the meeting. Members can submit names of such speakers to ISGIDAR officers, who will select from the submitted suggestions. It was agreed that the areas of research interest of these invited speakers may be broader than that usually represented at ISGIDAR, including, for example, alcohol/alcoholism research or other topics that are of interest to ISGIDAR and CPDD. Members were all in favor of this motion.

ISGIDAR has been invited by Vice-President Tomoji Yanagita to submit a proposal for a symposium at the 1990 meeting of the Congress Collegium Internationale Neuro-Psychopharmacologicum (CINP) in Kyoto, Japan. Persons interested in participating in this symposium were encouraged to submit an abstract to President Ator by the end of July.

President Ator presented the proposed revision of the ISGIDAR bylaws to the membership, and discussed highlights of the changes. In this context, the importance of ISGIDAR'S status as a membership organization, especially at it affects our relation to CPDD, was re-affirmed. A mechanism for rescinding membership was considered important and therefore retained. A more formal mechanism for accepting new members was agreed on, which is described below under "New Membership Procedures". Bill Woolverton moved and Harriet de Wit seconded that the
A MESSAGE FROM THE PRESIDENT

My thanks to all the speakers who presented papers at the 1988 meeting of ISGIDAR. Special thanks are also due to Dr. Marty Adler, the Executive Secretary of CPDD. His efforts and his warm support of ISGIDAR have been of tremendous help in planning our meeting.

My thanks also to all the members who stayed for the Business Meeting and contributed their views and ideas on the issues presented. One particularly innovative idea agreed upon at this year’s meeting was to offer honoraria to up to five persons engaged in research related to drug reinforcement who have not been actively involved in ISGIDAR in recent years but who would be invited to speak at the 1989 ISGIDAR meeting. There was also a consensus that anyone currently active in drug reinforcement research who is not a member should be invited to attend the 1989 meeting and to join ISGIDAR. I might add that an area of particular emphasis in this regard should be researchers working in countries other than the U.S. so as to maintain our “international flavor” (especially now that our treasurer no longer resides in Switzerland).

Some members have already given me names of researchers who should be formally invited to attend next year’s ISGIDAR meeting and be considered as candidates for the special honoraria for invited speakers. I encourage all of you to submit ideas for such speakers to me as soon as they occur to you. I will need to send the invitations out early in 1989—possibly before the January edition of the Newsletter reaches you.

As requested by the membership at the 1987 business meeting, I will continue to monitor federal legislation and regulation that may impact research with animal subjects. The recent efforts of researchers and their professional organizations to provide information to legislators and regulators that will give them a balanced view of animal rights issues has met with some success in the past year. One example of the way in which such lobbying is helpful is that Senator Wendell Ford of Kentucky was persuaded to withdraw his “Pet Protection Act” (S 1457) and submit instead the “Pet Theft Act” (S 2353). The original bill would have established, “...that any person obtaining or using for any research purpose any animal acquired from any animal shelter shall not be eligible to receive any (NIH) grant or research protocol...”. The new bill is much more narrowly drawn to “prohibit the selling of stolen dogs and cats” and puts the responsibility for compliance on the dealers. Aside from pending legislation, an issue of concern is the content of the regulations currently being drafted within the USDA. These include (1) the revised animal care regulation and (2) newly drafted regulation pertaining to the psychological well-being of laboratory primates. The public comment period will begin when these are published in the Federal Register. Our latest information is that the new regulations have been drafted but will not be available for public comment until after November. With the advice of the Board of Officers, I will draft comment letters on behalf of ISGIDAR. We will welcome any analysis or comment from ISGIDAR members with respect to what they would like to see included in the comment letters.
ISGIDAR BIBLIOGRAPHY

Listing of recent publications or manuscripts in press on the behavioral pharmacology of drugs of abuse by ISGIDAR members:

RA = published, reprints available
IP = in press
SU = submitted
NA = published, reprints not available

Dr. Marilyn E. Carroll
Psychiatry Department
Mayo Box 392
University of Minnesota
Minneapolis, MN 55455


Dr. William A. Corrigall
Neurobiology Section
Addiction Research Foundation
333 Russell Street
Toronto, Ontario Canada M5S 2S1


Dr. Roland Griffiths
Division of Behavioral Biology
The Johns Hopkins University School of Medicine
720 Rutland Avenue, Room 623
Baltimore, MD 21205


Dr. James H. Woods
Department of Pharmacology
The University of Michigan Medical School
Ann Arbor, MI 48109-0626


Woolverton, W.L. and Kleven, M.S. Evidence for cocaine dependence in monkeys following a prolonged period of exposure. Psychopharmacology 94: 286, 1986. (RA)

Kleven, M.S., Woolverton, W.L. and Selden, L.S. Lack of long-term monoamine depletions following repeated or continuous exposure to cocaine. Brain Research, 1988. (IP)

Kleven, M.S., Anthony, E.W., Goldberg, L.I. and Woolverton, W.L. Blockade of the discriminative stimulus effects of cocaine in rhesus monkeys with the D1 dopamine antagonist SCH 23390. Psychopharmacology. (IP)


Nencini, P. and Woolverton, W.L. Effects of nimodipine, a calcium channel blocker on the discriminative stimulus properties of d-amphetamine in rats. Psychopharmacology. (SU)


Woolverton, W.L. and Virus, R.M. The effects of D1 and D2 dopamine antagonists on behavior maintained by cocaine or food. Pharmacology Biochemistry and Behavior, 1988. (SU)


Dr. Tomoji Yanagita
Director,
Preclinical Research Laboratories
Central Institute for Experimental Animals
1433 Nogawa
Kawasaki, Japan 213

Message from the President.

My thanks to all the speakers who presented papers at the 1988 meeting of ISGIDAR. Special thanks is also due to Dr. Marty Adler, the Executive Secretary of CADD. His efforts and his warm support of ISGIDAR have been of tremendous help in planning our meetings.

My thanks also to all the members who stayed for the Business Meeting and contributed their views and ideas on the issues presented. One particularly innovative idea agreed upon at this year's meeting was to offer honoraria to up to five persons engaged in research related to drug reinforcement who have not been actively involved in ISGIDAR in recent years but who would be invited to speak at the 1989 ISGIDAR meeting. There was also a consensus that anyone currently active in drug reinforcement research who is not a member should be invited to attend the 1989 meeting and to join ISGIDAR. I might add that an area of particular emphasis is this regard should be researchers working in countries other than the U.S. so as to maintain our "international flavor" (especially now that our treasurer no longer resides in Switzerland!).

Some members have already given me the names of researchers who should be formally invited to attend next year's ISGIDAR meeting and be considered as candidates for the special honoraria for invited speakers. I encourage all of you to submit ideas for such speakers to me as soon as they occur to you. I will need to send the invitations out early in 1989--possibly before the January edition of the Newsletter reaches you.

At requested by the membership at the 1987 business meeting, I will continue to monitor federal legislation and regulation that may impact research with animal subjects. The recent efforts of researchers and their professional organizations to provide information to legislators and regulators that will give them a balanced view of animal rights issues has met with some success in the past year. One example of the way in which such lobbying is helpful is that Senator Wendell Ford of Kentucky was persuaded to withdraw his "Pet Protection Act" (S 1457) and submit instead the "Pet Theft Act" (S 2353). The original bill would have established, "...that any person obtaining or using for any research purpose any animal acquired from any animal shelter shall not be eligible to receive any [NIH] grant or research protocol." The new bill is much more narrowly drawn to "prohibit the selling of stolen dogs and cats" and puts the responsibility for compliance on the dealers. Aside from pending legislation, an issue of concern is the content of the regulations currently being drafted within the USDA. These include (1) the revised animal care regulations and (2) newly drafted regulations pertaining to the psychological well-being of laboratory primates. The public comment period will begin when these are published in the Federal Register. With the advice of the Board of Officers, I will draft comment letters on behalf of ISGIDAR. We will welcome any analysis or comment from ISGIDAR members with respect to what they would like to see included in the comment letters.